Screener
Axsome Therapeutics AXSM Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 250,731 | 232,853 |
| Operating lease liability, current portion | 628 | 434 |
| Contingent consideration, current | 11,150 | 10,012 |
| Short-term borrowings | 70,000 | 70,000 |
| Total current liabilities | 439,211 | 378,836 |
| Contingent consideration, non-current | 73,730 | 77,540 |
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's current debt?
- Axsome Therapeutics (AXSM) reported current debt of $70M in Q1 2026.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Axsome Therapeutics's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude